PulmoGeniX™ Technologies, Inc. is a technology licensing and joint development relationship forged between Mayo Clinic and Sanovas, Inc. to commercialize significant innovations to treat and cure the most severe cases of asthma.



The PulmoGeniX system is a first-in-kind suite of diagnostic and therapeutic tools for Bronchial Smooth Muscle Modification Therapy. 



Bronchial thermoplasty is a new treatment for severe asthma in patients whose asthma isn't well controlled with inhaled corticosteroids and beta agonists

Severe Asthma Attack


The acute, chronic asthma patient population is represented by more than 2 million severe asthma patients in the U.S. and 8 million worldwide

Larry Gerrans

“The spirit of this collaboration is to combine Sanovas’ and Mayo Clinic’s respective technologies and expertise to advance precision in the treatment and control of asthma for patients with severe persistent asthma. We expect to commercialize an intelligent set of next generation tools that will afford clinicians an intuitive command of the operating environment. We welcome Mayo Clinic’s participation in both the inception of certain aspects of the technology and their ongoing participation in the development, clinical investigation and study of the technology.” 

— Larry Gerrans, CEO of Sanovas


Craig Daniels

"Working together with Sanovas exemplifies how industry collaborations support today’s new era of evidence-based medicine. The development of a single treatment system that can be performed with precision and that can offer real time feedback of treatment efficacy in a single office visit, versus the three treatments that are currently required benefits patients and providers because it will reduce risk and save time and money.”
— Craig E. Daniels M.D., associate professor of pulmonary and critical care medicine at Mayo Clinic